Evidence map›Paper›PMID 39140037›Full record

ArticleACS medicinal chemistry letters2024

Development of Novel Bacterial Topoisomerase Inhibitors Assisted by Computational Screening.

Joshua W Powell, Chelsea A Mann, Paul D Toth, Sheri Nolan, Anja Steinert, Clarissa Ove, Justin T Seffernick, Daniel J Wozniak, Razieh Kebriaei, Steffen Lindert and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Joshua W PowellDivision of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States.
Chelsea A MannDivision of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States.
Paul D TothDivision of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States.
Sheri NolanDivision of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States.
Anja SteinertDivision of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States.
Clarissa OveDivision of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States.
Justin T SeffernickDivision of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States.
Daniel J WozniakDivision of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States.
Razieh KebriaeiDivision of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States.
Steffen LindertDivision of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States.ORCID https://orcid.org/0000-0002-3976-3473
Neil OsheroffDepartment of Biochemistry and Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0002-2550-4884
Jack C YalowichDivision of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States.
Mark J Mitton-FryDivision of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States.ORCID https://orcid.org/0000-0002-6715-8836

Funding

Mechanistic Studies of Gyrase/Topoisomerase IV-Targeted AntibacterialsR01AI170546 · NIAID · VANDERBILT UNIVERSITY · PI NEIL OSHEROFF · 2023 to 2026
$2.7M
Mechanistic Studies of Type II Topoisomerases and Topoisomerase-Targeted AgentsR01GM126363 · NIGMS · VANDERBILT UNIVERSITY · PI OSHEROFF, NEIL · 2018 to 2025
$2.6M
Overcoming Resistance to Novel Bacterial Topoisomerase InhibitorsR01AI173072 · NIAID · OHIO STATE UNIVERSITY · PI Mark J. Mitton-Fry · 2023 to 2026
$2.4M
Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Negative BacteriaR21AI148986 · NIAID · OHIO STATE UNIVERSITY · PI MITTON-FRY, MARK J. · 2020 to 2021
$429k
NIAID NIH HHS R01 AI170546NIAID NIH HHS R01 AI173072NIAID NIH HHS R21 AI148986NIGMS NIH HHS R01 GM126363
6 · The paper itself

Abstract

Multidrug-resistant bacterial infections pose an ever-evolving threat to public health. Since the outset of the antibacterial age, bacteria have developed a multitude of diverse resistance mechanisms that suppress the effectiveness of current therapies. New drug entities, such as Novel Bacterial Topoisomerase Inhibitors (NBTIs), can circumvent this major issue. A computational docking model was employed to predict the binding to DNA gyrase of atypical NBTIs with novel pharmacophores. Synthesis of NBTIs based on computational docking and subsequent antibacterial evaluation against both Gram-positive and Gram-negative bacteria yielded congeners with outstanding anti-staphylococcal activity and varying activity against select Gram-negative pathogens.

Identifiers

PMID39140037
PMCPMC11318591

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.